CERo Therapeutics Doses Patient in Phase 1 Trial

CERo Therapeutics has successfully dosed the third patient in Cohort 2 of its Phase 1 trial for CER-1236. This trial is investigating the therapeutic potential of CER-1236 in patients with myelodysplastic syndrome (MDS) and myelofibrosis (MF). The study is progressing as planned and will soon advance into expanded patient populations. This milestone indicates positive momentum in the clinical development of CER-1236, bringing the company closer to potentially offering new treatment options for these challenging hematological conditions.